Peroxisome proliferator-activated receptor gamma as a drug target in the pathogenesis of insulin resistance

Pharmacology and Therapeutics

Volumn 111, Issue 1, 2006, Pages 145-173

  Guo, Liang ^a   Tabrizchi, Reza ^a  

^a MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

Author keywords

Cytokines; Free fatty acids; Insulin resistance; Obesity; Peroxisome proliferator activated receptor gamma; thiazolidinedione

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; 5 (2,4 DIOXO 5 THIAZOLIDINYLMETHYL) 2 METHOXY N [4 (TRIFLUOROMETHYL)BENZYL]BENZAMIDE; ADIPONECTIN; CBL PROTEIN; FATTY ACID; GLUCOSE TRANSPORTER 4; INSULIN; INSULIN RECEPTOR; INTERLEUKIN 6; ISOPROTEIN; LEPTIN; LIGAND; LY 465608; MANDELIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PHOSPHOPROTEIN PHOSPHATASE 1; PLASMINOGEN ACTIVATOR INHIBITOR 1; RAGAGLITAZAR; RESISTIN; SERINE; TELMISARTAN; TUMOR NECROSIS FACTOR ALPHA; TYROSINE; UNCLASSIFIED DRUG;

ADIPOCYTE; ADIPOGENESIS; ANEMIA; ATHEROSCLEROSIS; CARCINOGENESIS; CARDIOVASCULAR SYSTEM; COMORBIDITY; CONGESTIVE HEART FAILURE; DISEASE ASSOCIATION; DRUG EFFECT; DRUG TARGETING; DYSLIPIDEMIA; FATTY ACID BLOOD LEVEL; FLUID RETENTION; GASTROINTESTINAL SYMPTOM; GENE CONTROL; GENE EXPRESSION; GENE TARGETING; GENETIC TRANSCRIPTION; HOMEOSTASIS; HUMAN; HYPERTENSION; HYPERTROPHY; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIVER TOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATHOGENESIS; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; PROTEIN STRUCTURE; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; UPPER RESPIRATORY TRACT INFECTION; UROGENITAL TRACT DISEASE; WEIGHT GAIN;

ANIMALS; HUMANS; INSULIN; INSULIN RESISTANCE; PPAR GAMMA; THIAZOLIDINEDIONES;

EID: 33646776061     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2005.10.009     Document Type: Review

References (356)

1. Adams M., Reginato M.J., Shao D., Lazar M.A., and Chatterjee V.K. Transcriptional activation by peroxisome proliferator-activated receptor gamma is inhibited by phosphorylation at a consensus mitogen-activated protein kinase site. J Biol Chem 272 (1997) 5128-5132
2. Adams A.D., Hu Z., von Langen D., Dadiz A., Elbrecht A., MacNaul K.L., et al. O-arylmandelic acids as highly selective human PPAR alpha/gamma agonists. Bioorg Med Chem Lett 13 (2003) 3185-3190
3. Aguirre V., Uchida T., Yenush L., Davis R., and White M.F. The c-Jun NH (2)-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser (307). J Biol Chem 275 (2000) 9047-9054
4. Ahima R.S., and Flier J.S. Leptin. Annu Rev Physiol 62 (2000) 413-437
5. Ahima R.S., and Flier J.S. Adipose tissue as an endocrine organ. Trends Endocrinol Metab 11 (2000) 3232-3273
6. Ahmad F., and Goldstein B.J. Effect of tumor necrosis factor-alpha on the phosphorylation of tyrosine kinase receptors is associated with dynamic alterations in specific protein-tyrosine phosphatases. J Cell Biochem 64 (1997) 117-127
7. Alessi M.C., and Juhan-Vague I. Contribution of PAI-1 in cardiovascular pathology. Arch Mal Coeur Vaiss 97 (2004) 673-678
8. Altshuler D., Hirschhorn J.N., Klannemark M., Lindgren C.M., Vohl M.C., Nemesh J., et al. The common PPAR-gamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 26 (2000) 76-80
9. Anastassios G.P., Nandini A.J., and Andrew S.G. Adipocytokines and insulin resistance. J Clin Endocrinol Metab 89 (2004) 447-452
10. Arakawa K., Ishihara T., Aoto M., Inamasu M., Kitamura K., and Saito A. An antidiabetic thiazolidinedione induces eccentric cardiac hypertrophy by cardiac volume overload in rats. Clin Exp Pharmacol Physiol 31 (2004) 8-13
11. Asakawa M., Takano H., Nagai T., Uozumi H., Hasegawa H., Kubota N., et al. Peroxisome proliferator-activated receptor gamma plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo. Circulation 105 (2002) 1240-1246
12. Aubry C.E., Hammar E., Siegrist-Kaiser C., Pernin A., Takeshita A., Chin W.W., et al. Regulation of the transcriptional activity of the peroxisome proliferator-activated receptor alpha by phosphorylation of a ligand-independent trans-activating domain. J Biol Chem 274 (1999) 10505-10510
13. Auwerx J. PPAR gamma, the ultimate thrifty gene. Diabetologia 42 (1999) 1033-1049
14. Azen S.P., Peters R.K., Berkowitz K., Kjos S., Xiang A., and Buchanan T.A. TRIPOD (troglitazone in the prevention of diabetes): a randomized, placebo-controlled trial of troglitazone in women with prior gestational diabetes mellitus. Control Clin Trials 19 (1998) 217-231
15. Bajaj M., Suraamornkul S., Hardies L.J., Pratipanawatr T., and DeFronzo R.A. Plasma resistin concentration, hepatic fat content, and hepatic and peripheral insulin resistance in pioglitazone-treated type II diabetic patients. Int J Obes 28 (2004) 783-789
16. Barroso I., Gurnell M., Crowley V.E., Agostini M., Schwabe J.W., Soos M.A., et al. Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 402 (1999) 880-883
17. Bastard J.P., Jardel C., Bruckert E., Blondy P., Capeau J., Laville M., et al. Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss. J Clin Endocrinol Metab 85 (2000) 3338-3342
18. Baumann C.A., Chokshi N., Saltiel A.R., and Ribon V. Cloning and characterization of a functional peroxisome proliferator activator receptor-gamma-responsive element in the promoter of the CAP gene. J Biol Chem 275 (2000) 9131-9135
19. Beale E.G., Hammer R.E., Antoine B., and Forest C. Glyceroneogenesis comes of age. FASEB J 16 (2002) 1695-1696
20. Becker A.B., and Roth R.A. Insulin receptor structure and function in normal and pathological conditions. Annu Rev Med 41 (1990) 99-115
21. Bell D., and McDermott B.J. Effects of rosiglitazone and interactions with growth-regulating factors in ventricular cell hypertrophy. Eur J Pharmacol 508 (2005) 69-76
22. Benbow A., Stewart M., and Yeoman G. Thiazolidinediones for type 2 diabetes. All glitazones may exacerbate heart failure. BMJ 322 (2001) 236
23. Berg A.H., Combs T.P., Du X., Brownlee M., and Scherer P.E. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 7 (2001) 947-953
24. Berger J., and Moller D.E. The mechanisms of action of PPARs. Annu Rev Med 53 (2002) 409-435
25. Berger J., Bailey P., Biswas C., Cullinan C.A., Doebber T.W., Hayes N.S., et al. Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-gamma: binding and activation correlate with antidiabetic actions in db/db mice. Endocrinology 137 (1996) 4189-4195
26. Berger J., Tanen M., Elbrecht A., Hermanowski-Vosatka A., Moller D.E., Wright S.D., et al. Peroxisome proliferator-activated receptor-gamma ligands inhibit adipocyte 11-beta-hydroxysteroid dehydrogenase type 1 expression and activity. J Biol Chem 276 (2001) 12629-12635
27. Boden G., Jadali F., White J., Liang Y., Mozzoli M., Chen X., et al. Effects of fat on insulin-stimulated carbohydrate metabolism in normal men. J Clin Invest 88 (1991) 960-966
28. Bogacka I., Xie H., Bray G.A., and Smith S.R. The effect of pioglitazone on peroxisome proliferator-activated receptor-gamma target genes related to lipid storage in vivo. Diabetes Care 27 (2004) 1660-1667
29. Bonen A., Campbell S.E., Benton C.R., Chabowski A., Coort S.L., Han X.X., et al. Regulation of fatty acid transport by fatty acid translocase/CD36. Proc Nutr Soc 63 (2004) 245-249
30. Borst S.E. The role of TNF-alpha in insulin resistance. Endocrine 23 (2004) 177-182
31. Brady M.J., and Saltiel A.R. The role of protein phosphatase-1 in insulin action. Recent Prog Horm Res 56 (2001) 157-173
32. Braissant O., Foufelle F., Scotto C., Dauca M., and Wahli W. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology 137 (1996) 354-366
33. Buchanan T.A., Meehan W.P., Jeng Y.Y., Yang D., Chan T.M., Nadler J.L., et al. Blood pressure lowering by pioglitazone. Evidence for a direct vascular effect. J Clin Invest 96 (1995) 354-360
34. Buechler C., Ritter M., Duong C.Q., Orso E., Kapinsky M., and Schmitz G. Adipophilin is a sensitive marker for lipid loading in human blood monocytes. Biochim Biophys Acta 1532 (2001) 97-104
35. Camp H.S., Li O., Wise S.C., Hong Y.H., Frankowski C.L., Shen X., et al. Differential activation of peroxisome proliferator-activated receptor-gamma by troglitazone and rosiglitazone. Diabetes 49 (2000) 539-547
36. Cao Z., Umek R.M., and McKnight S.L. Regulated expression of three C/EBP isoforms during adipose conversion of 3T3-L1 cells. Genes Dev 5 (1991) 1538-1552
37. Cardillo C., Nambi S.S., Kilcoyne C.M., Choucair W.K., Katz A., Quon M.J., et al. Insulin stimulates both endothelin and nitric oxide activity in the human forearm. Circulation 100 (1999) 820-825
38. Ceddia R.B., Koistinen H.A., Zierath J.R., and Sweeney G. Analysis of paradoxical observations on the association between leptin and insulin resistance. FASEB J 16 (2002) 1163-1176
39. Chakrabarti R., Vikramadithyan R.K., Misra P., Hiriyan J., Raichur S., Damarla R.K., et al. Ragaglitazar: a novel PPAR alpha PPAR gamma agonist with potent lipid-lowering and insulin-sensitizing efficacy in animal models. Br J Pharmacol 140 (2003) 527-537
40. Chalasani N., Teal E., and Hall S.D. Effect of rosiglitazone on serum liver biochemistries in diabetic patients with normal and elevated baseline liver enzymes. Am J Gastroenterol 100 (2005) 1317-1321
41. Cheng A.Y., and Fantus I.G. Thiazolidinedione-induced congestive heart failure. Ann Pharmacother 38 (2004) 817-820
42. Clarke J.F., Young P.W., Yonezawa K., Kasuga M., and Holman G.D. Inhibition of the translocation of GLUT1 and GLUT4 in 3T3-L1 cells by the phosphatidylinositol 3-kinase inhibitor, wortmannin. Biochem J 300 (1994) 631-635
43. Cluxton Jr. R.J., Li Z., Heaton P.C., Weiss S.R., Zuckerman I.H., Moomaw C.J., et al. Impact of regulatory labeling for troglitazone and rosiglitazone on hepatic enzyme monitoring compliance: findings from the State of Ohio Medicaid Program. Pharmacoepidemiol Drug Saf 14 (2005) 1-9
44. Combs T.P., Wagner J.A., Berger J., Doebber T., Wang W.J., Zhang B.B., et al. Induction of adipocyte complement-related protein of 30 kilodaltons by PPARgamma agonists: a potential mechanism of insulin sensitization. Endocrinology 143 (2002) 998-1007
45. Considine R.V., Sinha M.K., Heiman M.L., Kriauciunas A., Stephens T.W., Nyce M.R., et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 334 (1996) 292-295
46. Cooper M.E. The role of the renin-angiotensin-aldosterone system in diabetes and its vascular complications. Am J Hypertens 17 (2004) S16-S20
47. Corton J.C., Anderson S.P., and Stauber A. Central role of peroxisome proliferator-activated receptors in the actions of peroxisome proliferators. Annu Rev Pharmacol Toxicol 40 (2000) 491-518
48. Cushman S.W., and Wardzala L.J. Potential mechanism of insulin action on glucose transport in the isolated rat adipose cell. Apparent translocation of intracellular transport systems to the plasma membrane. J Biol Chem 255 (1980) 4758-4762
49. Czekay R.P., and Loskutoff D.J. Unexpected role of plasminogen activator inhibitor 1 in cell adhesion and detachment. Exp Biol Med (Maywood) 229 (2004) 1090-1096
50. De Alvaro C., Teruel T., Hernandez R., and Lorenzo M. Tumor necrosis factor alpha produces insulin resistance in skeletal muscle by activation of inhibitor kappaB kinase in a p38 MAPK-dependent manner. J Biol Chem 279 (2004) 17070-17078
51. DeFronzo R.A., Bonadonna R.C., and Ferrannini E. Pathogenesis of NIDDM. A balanced overview. Diabetes Care 15 (1992) 318-368
52. Delea T.E., Edelsberg J.S., Hagiwara M., Oster G., and Phillips L.S. Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort study. Diabetes Care 26 (2003) 2983-2989
53. Delerive P., Berrebi-Bertrand I., Buckingham R.E., Staels B., and Bril A. Rosiglitazone, a peroxisome proliferator-activated receptor-gamma, inhibits the Jun NH(2)-terminal kinase/activating protein 1 pathway and protects the heart from ischemia/reperfusion injury. Diabetes 51 (2002) 1507-1514
54. Denton R.M., Brownsey R.W., and Belsham G.J. A partial view of the mechanism of insulin action. Diabetologia 21 (1981) 347-362
55. Desvergne B., and Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 20 (1999) 649-688
56. De Vos P., Lefebvre A.M., Miller S.G., Guerre-Millo M., Wong K., Saladin R., et al. Thiazolidinediones repress ob gene expression in rodents via activation of peroxisome proliferator-activated receptor gamma. J Clin Invest 98 (1996) 1004-1009
57. Dina R., and Jafari M. Angiotensin II-receptor antagonists: an overview. Am J Health-Syst Pharm 57 (2000) 1231-1241
58. Dobrian A.D., Schriver S.D., Khraibi A.A., and Prewitt R.L. Pioglitazone prevents hypertension and reduces oxidative stress in diet-induced obesity. Hypertension 43 (2004) 48-56
59. Doggrell S.A. Telmisartan-killing two birds with one stone. Expert Opin Pharmacother 5 (2004) 2397-2400
60. Dresner A., Laurent D., Marcucci M., Griffin M.E., Dufour S., Cline G.W., et al. Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. J Clin Invest 103 (1999) 253-259
61. Dreyer C., Krey G., Keller H., Givel F., Helftenbein G., and Wahli W. Cell Control of the peroxisomal beta-oxidation pathway by a novel family of nuclear hormone receptors. Cell 68 (1992) 879-887
62. Duan S.Z., Ivashchenko C.Y., Russell M.W., Milstone D.S., and Mortensen R.M. Cardiomyocyte-specific knockout and agonist of peroxisome proliferator-activated receptor-gamma both induce cardiac hypertrophy in mice. Circ Res 97 (2005) 372-379
63. Duplomb L., Lee Y., Wang M.Y., Park B.H., Takaishi K., Agarwal A.K., et al. Increased expression and activity of 11beta-HSD-1 in diabetic islets and prevention with troglitazone. Biochem Biophys Res Commun 313 (2004) 594-599
64. Duval C., Chinetti G., Trottein F., Fruchart J.C., and Staels B. The role of PPARs in atherosclerosis. Trends Mol Med 8 (2002) 422-430
65. Eddy A.A. Plasminogen activator inhibitor-1 and the kidney. Am J Physiol Renal Physiol 283 (2002) F209-F220
66. Elbrecht A., Chen Y., Cullinan C.A., Hayes N., Leibowitz M., Moller D.E., et al. Molecular cloning, expression and characterization of human peroxisome proliferator activated receptors gamma 1 and gamma 2. Biochem Biophys Res Commun 224 (1996) 431-437
67. El-Jack A.K., Hamm J.K., Pilch P.F., and Farmer S.R. Reconstitution of insulin-sensitive glucose transport in fibroblasts requires expression of both PPAR gamma and C/EBPalpha. J Biol Chem 274 (1999) 7946-7951
68. Etgen G.J., Oldham B.A., Johnson W.T., Broderick C.L., Montrose C.R., Brozinick J.T., et al. A tailored therapy for the metabolic syndrome: the dual peroxisome proliferator-activated receptor-alpha/gamma agonist LY465608 ameliorates insulin resistance and diabetic hyperglycemia while improving cardiovascular risk factors in preclinical models. Diabetes 51 (2002) 1083-1087
69. Fajas L., Fruchart J.C., and Auwerx J. PPARgamma3 mRNA: a distinct PPARgamma mRNA subtype transcribed from an independent promoter. FEBS Lett 438 (1998) 55-60
70. Fajas L., Auboeuf D., Raspe E., Schoonjans K., Lefebvre A.M., Saladin R., et al. The organization, promoter analysis, and expression of the human PPARgamma gene. J Biol Chem 272 (1997) 18779-18789
71. Fernandez A.M., Kim J.K., Yakar S., Dupont J., Hernandez-Sanchez C., Castle A.L., et al. Functional inactivation of the IGF-I and insulin receptors in skeletal muscle causes type 2 diabetes. Genes Dev 15 (2001) 1926-1934
72. Fernandez-Sanchez M.E., Criado-Garcia O., Heath K.E., Garcia-Fojeda B., Medrano-Fernandez I., Gomez-Garre P., et al. Laforin, the dual-phosphatase responsible for Lafora disease, interacts with R5 (PTG), a regulatory subunit of protein phosphatase-1 that enhances glycogen accumulation. Hum Mol Genet 12 (2003) 3161-3171
73. Fonseca V. Effect of thiazolidinediones on body weight in patients with diabetes mellitus. Am J Med 115 (2003) S42-S48
74. Forman B.M., Tontonoz P., Chen J., Brun R.P., Spiegelman B.M., and Evans R.M. 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell 83 (1995) 803-812
75. Frantz S., Hu K., Widder J., Bayer B., Witzel C.C., Schmidt I., et al. Peroxisome proliferator activated-receptor agonism and left ventricular remodeling in mice with chronic myocardial infarction. Br J Pharmacol 141 (2004) 9-14
76. Frey N., and Olson E.N. Modulating cardiac hypertrophy by manipulating myocardial lipid metabolism?. Circulation 105 (2002) 1152-1154
77. Friedberg M., Zoumakis E., Hiroi N., Bader T., Chrousos G.P., and Hochberg Z. Modulation of 11ß-hydroxysteroid dehydrogenase type 1 in mature human subcutaneous adipocytes by hypothalamic messengers. J Clin Endocrinol Metab 88 (2003) 385-393
78. Frohnert B.I., Hui T.Y., and Bernlohr D.A. Identification of a functional peroxisome proliferator-responsive element in the murine fatty acid transport protein gene. J Biol Chem 274 (1999) 3970-3977
79. Fruebis J., Tsao T.S., Javorschi S., Ebbets-Reed D., Erickson M.R., Yen F.T., et al. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci U S A 98 (2001) 2005-2010
80. Fujita T., Sugiyama Y., Taketomi S., Sohda T., Kawamatsu Y., Iwatsuka H., et al. Reduction of insulin resistance in obese and/or diabetic animals by 5-[4-(1-methylcyclohexylmethoxy)benzyl]-thiazolidine-2,4-dione (ADD-3878, U-63,287, ciglitazone), a new antidiabetic agent. Diabetes 32 (1983) 804-810
81. Gao Z., Zhang X., Zuberi A., Hwang D., Quon M.J., Lefevre M., et al. Inhibition of insulin sensitivity by free fatty acids requires activation of multiple serine kinases in 3T3-L1 adipocytes. Mol Endocrinol 18 (2004) 2024-2034
82. Gazzano H., Kowalski A., Fehlmann M., and Van Obberghen E. Two different protein kinase activities are associated with the insulin receptor. Biochem J 216 (1983) 575-582
83. Ghazzi M.N., Perez J.E., Antonucci T.K., Driscoll J.H., Huang S.M., Faja B.W., et al. Cardiac and glycemic benefits of troglitazone treatment in NIDDM. The Troglitazone Study Group. Diabetes 46 (1997) 433-439
84. Glass C.K., and Rosenfeld M.G. The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev 14 (2000) 121-141
85. Green H., and Kehinde O. An established preadipose cell line and its differentiation in culture. II. Factors affecting the adipose conversion. Cell 5 (1975) 19-27
86. Green A., Dobias S.B., Walters D.J., and Brasier A.R. Tumor necrosis factor increases the rate of lipolysis in primary cultures of adipocytes without altering levels of hormone-sensitive lipase. Endocrinology 134 (1994) 2581-2588
87. Greenberg A.S., Nordan R.P., McIntosh J., Calvo J.C., Scow R.O., and Jablons D. Interleukin 6 reduces lipoprotein lipase activity in adipose tissue of mice in vivo and in 3T3-L1 adipocytes: a possible role for interleukin 6 in cancer cachexia. Cancer Res Cancer Res 52 (1992) 4113-4116
88. Gregoire F.M., Smas C.M., and Sul H.S. Understanding adipocyte differentiation. Physiol Rev 78 (1998) 783-809
89. Griffin M.E., Marcucci M.J., Cline G.W., Bell K., Barucci N., Lee D., et al. Free fatty acid-induced insulin resistance is associated with activation of protein kinase C theta and alterations in the insulin signaling cascade. Diabetes 48 (1999) 1270-1274
90. Grunfeld C., and Palladino Jr. M.A. Tumor necrosis factor: immunologic, antitumor, metabolic, and cardiovascular activities. Adv Intern Med 35 (1990) 45-72
91. Guan H.P., Li Y., Jensen M.V., Newgard C.B., Steppan C.M., and Lazar M.A. A futile metabolic cycle activated in adipocytes by antidiabetic agents. Nat Med 8 (2002) 1122-1128
92. Guan Y., Hao C., Cha D.R., Rao R., Lu W., Kohan D.E., et al. Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption. Nat Med 11 (2005) 861-866
93. Haffner S.M., Mykkanen L., Festa A., Burke J.P., and Stern M.P. Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects: implications for preventing coronary heart disease during the prediabetic state. Circulation 101 (2000) 975-980
94. Hamm J.K., el Jack A.K., Pilch P.F., and Farmer S.R. Role of PPAR gamma in regulating adipocyte differentiation and insulin-responsive glucose uptake. Ann N Y Acad Sci 892 (1999) 134-145
95. Haugen F., Jorgensen A., Drevon C.A., and Trayhurn P. Inhibition by insulin of resistin gene expression in 3T3-L1 adipocytes. FEBS Lett 507 (2001) 105-108
96. Hawkins M., Tonelli J., Kishore P., Stein D., Ragucci E., Gitig A., et al. Contribution of elevated free fatty acid levels to the lack of glucose effectiveness in type 2 diabetes. Diabetes 52 (2003) 2748-2758
97. Henke B.R., Blanchard S.G., Brackeen M.F., Brown K.K., Cobb J.E., Collins J.L., et al. N-(2-Benzoylphenyl)-l-tyrosine PPARgamma agonists: 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents. J Med Chem 41 (1998) 5020-5036
98. Heron-Milhavet L., Haluzik M., Yakar S., Gavrilova O., Pack S., Jou W.C., et al. Muscle-specific overexpression of CD36 reverses the insulin resistance and diabetes of MKR mice. Endocrinology 145 (2004) 4667-4676
99. Hi R., Osada S., Yumoto N., and Osumi T. Characterization of the amino-terminal activation domain of peroxisome proliferator-activated receptor alpha. Importance of alpha-helical structure in the transactivating function. J Biol Chem 274 (1999) 35152-35158
100. Hirakata M., Tozawa R., Imura Y., and Sugiyama Y. Comparison of the effects of pioglitazone and rosiglitazone on macrophage foam cell formation. Biochem Biophys Res Commun 323 (2004) 782-788
101. Holcomb I.N., Kabakoff R.C., Chan B., Baker T.W., Gurney A., Henzel W., et al. FIZZ1, a novel cysteine-rich secreted protein associated with pulmonary inflammation, defines a new gene family. EMBO J 19 (2000) 4046-4055
102. Hollenberg N.K. Considerations for management of fluid dynamic issues associated with thiazolidinediones. Am J Med 115 (2003) S111-S115
103. Hong R., Philip D.GM., Christine M.L., Kenneth R., Todd R.G., and Jerrold M.O. Profiling gene transcription in vivo reveals adipose tissue as an immediate target of tumor necrosis factor-α: implications for insulin resistance. Diabetes 51 (2002) 3176-3188
104. Hong H.K., Cho Y.M., Park K.H., Lee C.T., Lee H.K., and Park K.S. Peroxisome proliferator-activated receptor gamma mediated inhibition of plasminogen activator inhibitor type 1 production and proliferation of human umbilical vein endothelial cells. Diabetes Res Clin Pract 62 (2003) 1-8
105. Hosokawa M., Tsukada H., Fukuda K., Oya M., Onomura M., Nakamura H., et al. Troglitazone inhibits bicarbonate secretion in rat and human duodenum. J Pharmacol Exp Ther 290 (1999) 1080-1084
106. Hotamisligil G.S., Shargill N.S., and Spiegelman B.M. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 259 (1993) 87-91
107. Hotamisligil G.S., Budavari A., Murray D., and Spiegelman B.M. Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes. Central role of tumor necrosis factor-alpha. J Clin Invest 94 (1994) 1543-1549
108. Hotamisligil G.S., Murray D.L., Choy L.N., and Spiegelman B.M. Tumor necrosis factor alpha inhibits signaling from the insulin receptor. Proc Natl Acad Sci U S A 91 (1994) 4854-4858
109. Hotamisligil G.S., Arner P., Caro J.F., Atkinson R.L., and Spiegelman B.M. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 95 (1995) 2409-2415
110. Hotamisligil G.S., Peraldi P., Budavari A., Ellis R., White M.F., and Spiegelman B.M. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-α-and obesity-induced insulin resistance. Science 271 (1996) 665-668
111. Hou B., Eren M., Painter C.A., Covington J.W., Dixon J.D., Schoenhard J.A., et al. Tumor necrosis factor alpha activates the human plasminogen activator inhibitor-1 gene through a distal nuclear factor kappaB site. J Biol Chem 279 (2004) 18127-18136
112. Hu E., Liang P., and Spiegelman B.M. AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem 271 (1996) 10697-10703
113. Huang A., and Raskin P. Thiazolidinediones and insulin: rationale for use and role of combination therapy in type 2 diabetes mellitus. Treat Endocrinol 4 (2005) 205-220
114. Iacobellis G., Ribaudo M.C., Zappaterreno A., Vecci E., Tiberti C., Di Mario U., et al. Relationship of insulin sensitivity and left ventricular mass in uncomplicated obesity. Obes Res 11 (2003) 518-524
115. Idris I., Gray S., and Donnelly R. Rosiglitazone and pulmonary oedema: an acute dose-dependent effect on human endothelial cell permeability. Diabetologia 46 (2003) 288-290
116. Imoto H., Imamiya E., Momose Y., Sugiyama Y., Kimura H., and Sohda T. Studies on non-thiazolidinedione antidiabetic agents: 1. Discovery of novel oxyiminoacetic acid derivatives. Chem Pharm Bull (Tokyo) 50 (2002) 1349-1357
117. Imoto H., Sugiyama Y., Kimura H., and Momose Y. Studies on non-thiazolidinedione antidiabetic agents: 2. Novel oxyiminoalkanoic acid derivatives as potent glucose and lipid lowering agents. Chem Pharm Bull (Tokyo) 51 (2003) 138-151
118. Inzucchi S.E., Masoudi F.A., Wang Y., Kosiborod M., Foody J.M., Setaro J.F., et al. Insulin-sensitizing antihyperglycemic drugs and mortality after acute myocardial infarction: insights from the National Heart Care Project. Diabetes Care 28 (2005) 1680-1689
119. Issemann I., and Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347 (1990) 645-650
120. Issemann I., Prince R.A., Tugwood J.D., and Green S. The retinoid X receptor enhances the function of the peroxisome proliferator activated receptor. Biochimie 75 (1993) 251-256
121. Iwata M., Haruta T., Usui I., Takata Y., Takano A., Uno T., et al. Pioglitazone ameliorates tumor necrosis factor-alpha-induced insulin resistance by a mechanism independent of adipogenic activity of peroxisome proliferator-activated receptor-gamma. Diabetes 50 (2001) 1083-1092
122. Iwaki M., Matsuda M., Maeda N., Funahashi T., Matsuzawa Y., Makishima M., et al. Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. Diabetes 52 (2003) 1655-1663
123. Jhun B.H., Rampal A.L., Liu H., Lachaal M., and Jung C.Y. Effects of insulin on steady state kinetics of GLUT4 subcellular distribution in rat adipocytes. Evidence of constitutive GLUT4 recycling. J Biol Chem 267 (1992) 17710-17715
124. Jiang C., Ting A.T., and Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 391 (1998) 82-86
125. Jiang T., Sweeney G., Rudolf M.T., Klip A., Traynor-Kaplan A., and Tsien R.Y. Membrane-permeant esters of phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 273 (1998) 11017-11024
126. Jones P.S., Savory R., Barratt P., Bell A.R., Gray T.J., Jenkins N.A., et al. Chromosomal localisation, inducibility, tissue-specific expression and strain differences in three murine peroxisome-proliferator-activated-receptor genes. Eur J Biochem 233 (1995) 219-226
127. Jucker B.M., Rennings A.J., Cline G.W., and Shulman G.I. 13C and 31P NMR studies on the effects of increased plasma free fatty acids on intramuscular glucose metabolism in the awake rat. J Biol Chem 272 (1997) 10464-10473
128. Kahn C.R. Diabetes. Causes of insulin resistance. Nature 373 (1995) 384-385
129. Kalambokis G.N., Tsatsoulis A.A., and Tsianos E.V. The edematogenic properties of insulin. Am J Kidney Dis 44 (2004) 575-590
130. Kalhan S.C., Mahajan S., Burkett E., Reshef L., and Hanson R.W. Glyceroneogenesis and the source of glycerol for hepatic triacylglycerol synthesis in humans. J Biol Chem 276 (2001) 12928-12931
131. Kallen C.B., and Lazar M.A. Antidiabetic thiazolidinediones inhibit leptin (ob) gene expression in 3T3-L1 adipocytes. Proc Natl Acad Sci U S A 93 (1996) 5793-5796
132. Kanai F., Ito K., Todaka M., Hayashi H., Kamohara S., Ishii K., et al. Insulin-stimulated GLUT4 translocation is relevant to the phosphorylation of IRS-1 and the activity of PI3-kinase. Biochem Biophys Res Commun 195 (1993) 762-768
133. Kanety H., Feinstein R., Papa M.Z., Hemi R., and Karasik A. Tumor necrosis factor alpha-induced phosphorylation of insulin receptor substrate-1 (IRS-1). Possible mechanism for suppression of insulin-stimulated tyrosine phosphorylation of IRS-1. J Biol Chem 270 (1995) 23780-23784
134. Karter A.J., Ahmed A.T., Liu J., Moffet H.H., Parker M.M., Ferrara A., et al. Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort study: response to Delea et al. Diabetes Care 27 (2004) 850-851
135. Karter A.J., Ahmed A.T., Liu J., Moffet H.H., and Parker M.M. Pioglitazone initiation and subsequent hospitalization for congestive heart failure. Diabet Med 22 (2005) 986-993
136. Kasuga M., Zick Y., Blith D.L., Karlsson F.A., Haring H.U., and Kahn C.R. Insulin stimulation of phosphorylation of the beta subunit of the insulin receptor. Formation of both phosphoserine and phosphotyrosine. J Biol Chem 257 (1982) 9891-9894
137. Kato K., Satoh H., Endo Y., Yamada D., Midorikawa S., Sato W., et al. Thiazolidinediones down-regulate plasminogen activator inhibitor type 1 expression in human vascular endothelial cells: a possible role for PPARgamma in endothelial function. Biochem Biophys Res Commun 258 (1999) 431-435
138. Keller H., Dreyer C., Medin J., Mahfoudi A., Ozato K., and Wahli W. Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator-activated receptor-retinoid X receptor heterodimers. Proc Natl Acad Sci U S A 90 (1993) 2160-2164
139. Kermani A., and Garg A. Thiazolidinedione-associated congestive heart failure and pulmonary edema. Mayo Clin Proc 78 (2003) 1088-1091
140. Khandoudi N., Delerive P., Berrebi-Bertrand I., Buckingham R.E., Staels B., and Bril A. Rosiglitazone, a peroxisome proliferator-activated receptor-gamma, inhibits the Jun NH(2)-terminal kinase/activating protein 1 pathway and protects the heart from ischemia/reperfusion injury. Diabetes 51 (2002) 1507-1514
141. Kim K.H., Lee K., Moon Y.S., and Sul H.S. A cysteine-rich adipose tissue-specific secretory factor inhibits adipocyte differentiation. J Biol Chem 276 (2001) 11252-11256
142. Kliewer S.A., Umesono K., Noonan D.J., Heyman R.A., and Evans R.M. Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature 358 (1992) 771-774
143. Kliewer S.A., Sundseth S.S., Jones S.A., Brown P.J., Wisely G.B., Koble C.S., et al. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. Proc Natl Acad Sci U S A 94 (1997) 4318-4323
144. Koh-Banerjee P., Wang Y., Hu F.B., Spiegelman D., Willett W.C., and Rimm E.B. Changes in body weight and body fat distribution as risk factors for clinical diabetes in US men. Am J Epidemiol 159 (2004) 1150-1159
145. Komers R., and Vrana A. Thiazolidinediones-tools for the research of metabolic syndrome X. Physiol Res 47 (1998) 215-225
146. Krook A., Wallberg-Henriksson H., and Zierath J.R. Sending the signal: molecular mechanisms regulating glucose uptake. Med Sci Sports Exerc 36 (2004) 1212-1217
147. Kruszynska Y.T., Worrall D.S., Ofrecio J., Frias J.P., Macaraeg G., and Olefsky J.M. Fatty acid-induced insulin resistance: decreased muscle PI3K activation but unchanged Akt phosphorylation. J Clin Endocrinol Metab 87 (2002) 226-234
148. Kurtz T.W. Treating the metabolic syndrome: telmisartan as a peroxisome proliferator-activated receptor-gamma activator. Acta Diabetol 42 (2005) S9-S16
149. Kushibiki S., Hodate K., Shingu H., Ueda Y., Shinoda M., Mori Y., et al. Insulin resistance induced in dairy steers by tumor necrosis factor alpha is partially reversed by 2, 4-thiazolidinedione. Domest Anim Endocrinol 21 (2001) 25-37
150. Lagathu C., Bastard J.P., Auclair M., Maachi M., Capeau J., and Caron M. Chronic interleukin-6 (IL-6) treatment increased IL-6 secretion and induced insulin resistance in adipocyte: prevention by rosiglitazone. Biochem Biophys Res Commun 311 (2003) 372-379
151. Lam K., Carpenter C.L., Ruderman N.B., Friel J.C., and Kelly K.L. The phosphatidylinositol 3-kinase serine kinase phosphorylates IRS-1. Stimulation by insulin and inhibition by Wortmannin. J Biol Chem 269 (1994) 20648-20652
152. Lang C.H., Dobrescu C., and Bagby G.J. Tumor necrosis factor impairs insulin action on peripheral glucose disposal and hepatic glucose output. Endocrinology 130 (1992) 43-52
153. Lebovitz H.E. Differentiating members of the thiazolidinedione class: a focus on safety. Diabetes Metab Res Rev 18 (2002) S23-S29
154. Lehmann J.M., Moore L.B., Smith-Oliver T.A., Wilkison W.O., Willson T.M., and Kliewer S.A. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 270 (1995) 12953-12956
155. Lehmann J.M., Lenhard J.M., Oliver B.B., Ringold G.M., and Kliewer S.A. Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem 272 (1997) 3406-3410
156. Leung M., Kwan D., and Evans M.F. Lifestyle intervention or treatment with metformin. Which delays onset of type 2 diabetes?. Can Fam Physician 50 (2004) 369-371
157. Li A.C., Binder C.J., Gutierrez A., Brown K.K., Plotkin C.R., Pattison J.W., et al. Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARalpha, beta/delta, and gamma. J Clin Invest 114 (2004) 1564-1576
158. Lillioja S., Mott D.M., Howard B.V., Bennett P.H., Yki-Jarvinen H., Freymond D., et al. Impaired glucose tolerance as a disorder of insulin action. Longitudinal and cross-sectional studies in Pima Indians. N Engl J Med 318 (1988) 1217-1225
159. Lillioja S., Mott D.M., Spraul M., Ferraro R., Foley J.E., Ravussin E., et al. Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective studies of Pima Indians. N Engl J Med 329 (1993) 1988-1992
160. Lin W.H., Chiu K.C., Chang H.M., Lee K.C., Tai T.Y., and Chuang L.M. Molecular scanning of the human sorbin and SH3-domain-containing-1 (SORBS1) gene: positive association of the T228A polymorphism with obesity and type 2 diabetes. Hum Mol Genet 10 (2001) 1753-1760
161. Liu R.H., Mizuta M., Kurose T., and Matsukura S. Early events involved in the development of insulin resistance in Zucker fatty rat. Int J Obes Relat Metab Disord 26 (2002) 318-326
162. Liu J., DeYoung S.M., Hwang J.B., O'Leary E.E., and Saltiel A.R. The roles of Cbl-b and c-Cbl in insulin-stimulated glucose transport. J Biol Chem 278 (2003) 36754-36762
163. Liu E., Kitajima S., Higaki Y., Morimoto M., Sun H., Watanabe T., et al. High lipoprotein lipase activity increases insulin sensitivity in transgenic rabbits. Metabolism 54 (2005) 132-138
164. Liu H.B., Hu Y.S., Medcalf R.L., Simpson R.W., and Dear A.E. Thiazolidinediones inhibit TNFalpha induction of PAI-1 independent of PPARgamma activation. Biochem Biophys Res Commun 334 (2005) 30-37
165. Liu H.R., Tao L., Gao E., Lopez B.L., Christopher T.A., Willette R.N., et al. Anti-apoptotic effects of rosiglitazone in hypercholesterolemic rabbits subjected to myocardial ischemia and reperfusion. Cardiovasc Res 62 (2004) 135-144
166. Long S.D., and Pekala P.H. Lipid mediators of insulin resistance:ceramide signalling down-regulates GLUT4 gene transcription in 3T3-L1 adipocytes. Biochem J 319 (1996) 179-184
167. Lopez-Alemany R., Redondo J.M., Nagamine Y., and Munoz-Canoves P. Plasminogen activator inhibitor type-1 inhibits insulin signaling by competing with alphavbeta3 integrin for vitronectin binding. Eur J Biochem 270 (2003) 814-821
168. Lusis A.J. Atherosclerosis. Nature 407 (2000) 233-241
169. Lygate C.A., Hulbert K., Monfared M., Cole M.A., Clarke K., and Neubauer S. The PPARgamma-activator rosiglitazone does not alter remodeling but increases mortality in rats post-myocardial infarction. Cardiovasc Res 58 (2003) 632-637
170. Ma L.J., Mao S.L., Taylor K.L., Kanjanabuch T., Guan Y., Zhang Y., et al. Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1. Diabetes 53 (2004) 336-346
171. Maeda N., Takahashi M., Funahashi T., Kihara S., Nishizawa H., Kishida K., et al. PPAR gamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 50 (2001) 2094-2099
172. Mangelsdorf D.J., Thummel C., Beato M., Herrlich P., Schutz G., Umesono K., et al. The nuclear receptor superfamily: the second decade. Cell 83 (1995) 835-839
173. Marcy T.R., Britton M.L., and Blevins S.M. Second-generation thiazolidinediones and hepatotoxicity. Ann Pharmacother 38 (2004) 1419-1423
174. Maruyoshi H., Kojima S., Funahashi T., Miyamoto S., Hokamaki J., Soejima H., et al. Adiponectin is inversely related to plasminogen activator inhibitor type 1 in patients with stable exertional angina. Thromb Haemost 91 (2004) 1026-1030
175. Masuzaki H., Paterson J., Shinyama H., Morton N.M., Mullins J.J., Seckl J.R., et al. A transgenic model of visceral obesity and the metabolic syndrome. Science 294 (2001) 2166-2170
176. Mather K., Anderson T.J., and Verma S. Insulin action in the vasculature: physiology and pathophysiology. J Vasc Res 38 (2001) 415-422
177. Mayer-Davis E.J., and Costacou T. Obesity and sedentary lifestyle: modifiable risk factors for prevention of type 2 diabetes. Curr Diabetes Rep 1 (2001) 170-176
178. Mayerson A.B., Hundal R.S., Dufour S., Lebon V., Befroy D., Cline G.W., et al. The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes 51 (2002) 797-802
179. McTernan P.G., Fisher F.M., Valsamakis G., Chetty R., Harte A., McTernan C.L., et al. Resistin and type 2 diabetes: regulation of resistin expression by insulin and rosiglitazone and the effects of recombinant resistin on lipid and glucose metabolism in human differentiated adipocytes. J Clin Endocrinol Metab 88 (2003) 6098-6106
180. Meriden T. Progress with thiazolidinediones in the management of type 2 diabetes mellitus. Clin Ther 26 (2004) 177-190
181. Meyer C., Woerle H.J., Dostou J.M., Welle S.L., and Gerich J.E. Abnormal renal, hepatic, and muscle glucose metabolism following glucose ingestion in type 2 diabetes. Am J Physiol Endocrinol Metab 287 (2004) E1049-E1056
182. Moeschel K., Beck A., Weigert C., Lammers R., Kalbacher H., Voelter W., et al. Protein kinase C-zeta-induced phosphorylation of Ser318 in insulin receptor substrate-1 (IRS-1) attenuates the interaction with the insulin receptor and the tyrosine phosphorylation of IRS-1. J Biol Chem 279 (2004) 25157-25163
183. Mohamed-Ali V., Goodrick S., Rawesh A., Katz D.R., Miles J.M., Yudkin J.S., et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab 82 (1997) 4196-4200
184. Moller D.E. New drug targets for type 2 diabetes and the metabolic syndrome. Nature 414 (2001) 821-827
185. Momoi A., Murao K., Imachi H., Sayo Y., Nakamura H., Hosokawa H., et al. Thiazolidinedione inhibits production of RANTES in a cytokine-treated human lung epithelial cell line. FEBS Lett 452 (1999) 301-304
186. Morton N.M., Holmes M.C., Fievet C., Staels B., Tailleux A., Mullins J.J., et al. Improved lipid and lipoprotein profile, hepatic insulin sensitivity, and glucose tolerance in 11beta-hydroxysteroid dehydrogenase type 1 null mice. J Biol Chem 276 (2001) 41293-41300
187. Morton N.M., Paterson J.M., Masuzaki H., Holmes M.C., Staels B., Fievet C., et al. Novel adipose tissue-mediated resistance to diet-induced visceral obesity in 11 beta-hydroxysteroid dehydrogenase type 1-deficient mice. Diabetes 53 (2004) 931-938
188. Mudaliar S., Chang A.R., and Henry R.R. Thiazolidinediones, peripheral edema, and type 2 diabetes: incidence, pathophysiology, and clinical implications. Endocr Pract 9 (2003) 406-416
189. Mukherjee R., Davies P.J., Crombie D.L., Bischoff E.D., Cesario R.M., Jow L., et al. Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists. Nature 386 (1997) 407-410
190. Muller G., Ayoub M., Storz P., Rennecke J., Fabbro D., and Pfizenmaier K. PKC zeta is a molecular switch in signal transduction of TNF-alpha, bifunctionally regulated by ceramide and arachidonic acid. EMBO J 14 (1995) 1961-1969
191. Munzberg H., Flier J.S., and Bjorbaek C. Region-specific leptin resistance within the hypothalamus of diet-induced obese mice. Endocrinology 145 (2004) 4880-4889
192. Murakami K., Tobe K., Ide T., Mochizuki T., Ohashi M., Akanuma Y., et al. A novel insulin sensitizer acts as a coligand for peroxisome proliferator-activated receptor-alpha (PPAR-alpha) and PPAR-gamma: effect of PPAR-alpha activation on abnormal lipid metabolism in liver of Zucker fatty rats. Diabetes 47 (1998) 1841-1847
193. Murao K., Imachi H., Momoi A., Sayo Y., Hosokawa H., Sato M., et al. Thiazolidinedione inhibits the production of monocyte chemoattractant protein-1 in cytokine-treated human vascular endothelial cells. FEBS Lett 454 (1999) 27-30
194. Muse E.D., Obici S., Bhanot S., Monia B.P., McKay R.A., Rajala M.W., et al. Role of resistin in diet-induced hepatic insulin resistance. J Clin Invest 114 (2004) 232-239
195. Negro R., Dazzi D., Hassan H., and Pezzarossa A. Pioglitazone reduces blood pressure in non-dipping diabetic patients. Minerva Endocrinol 29 (2004) 11-17
196. Nelson D.L., and Cox M.M. Chapter 21: lipid biosynthesis. Lehniger principles of biochemistry. 3rd ed. (2000), Worth publishers, New York 788-790
197. Nesto, R., & Libby, P. (2001). Chapter 63: diabetes mellitus and the cardiovascular system. In R. Nesto, & P. Libby, Braunwald's heart disease: a textbook of cardiovascular medicine (6th ed.)(pp. 2133-2150). Philadelphia: W.B. Saunders Company.
198. Nesto R.W., Bell D., Bonow R.O., Fonseca V., Grundy S.M., Horton E.S., et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Circulation 108 (2003, October 7) 2941-2948
199. Nielsen S., Guo Z., Johnson C.M., Hensrud D.D., and Jensen M.D. Splanchnic lipolysis in human obesity. J Clin Invest 113 (2004) 1582-1588
200. Nilsson P.M. Diabetes and obesity: new data on mechanisms and intervention trials. Expert Rev Cardiovasc Ther 3 (2005) 243-247
201. Nolte R.T., Wisely G.B., Westin S., Cobb J.E., Lambert M.H., Kurokawa R., et al. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma. Nature 395 (1998) 137-143
202. Oberfield J.L., Collins J.L., Holmes C.P., Goreham D.M., Cooper J.P., Cobb J.E., et al. A peroxisome proliferator-activated receptor gamma ligand inhibits adipocyte differentiation. Proc Natl Acad Sci U S A 96 (1999) 6102-6106
203. Ohshima T., Koga H., and Shimotohno K. Transcriptional activity of peroxisome proliferator-activated receptor gamma is modulated by SUMO-1 modification. J Biol Chem 279 (2004) 29551-29557
204. Okuno A., Tamemoto H., Tobe K., Ueki K., Mori Y., Iwamoto K., et al. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J Clin Invest 101 (1998) 354-1361
205. Olansky L., Marchetti A., and Lau H. Multicenter retrospective assessment of thiazolidinedione monotherapy and combination therapy in patients with type 2 diabetes: comparative subgroup analyses of glycemic control and blood lipid levels. Clin Ther 25 Suppl B (2003) 64-80
206. Olefsky J.M. The effects of spontaneous obesity on insulin binding, glucose transport, and glucose oxidation of isolated rat adipocytes. J Clin Invest 57 (1976) 842-851
207. Oleksiewicz M.B., Thorup I., Nielsen H.S., Andersen H.V., Hegelund A.C., Iversen L., et al. Generalized cellular hypertrophy is induced by a dual-acting PPAR agonist in rat urinary bladder urothelium in vivo. Toxicol Pathol 33 (2005) 552-560
208. Olswang Y., Cohen H., Papo O., Cassuto H., Croniger C.M., Hakimi P., et al. A mutation in the peroxisome proliferator-activated receptor gamma-binding site in the gene for the cytosolic form of phosphoenolpyruvate carboxykinase reduces adipose tissue size and fat content in mice. Proc Natl Acad Sci U S A 99 (2002) 625-630
209. Otarod J.K., and Goldberg I.J. Lipoprotein lipase and its role in regulation of plasma lipoproteins and cardiac risk. Curr Atheroscler Rep 6 (2004) 335-342
210. Patel L., Buckels A.C., Kinghorn I.J., Murdock P.R., Holbrook J.D., Plumpton C., et al. Resistin is expressed in human macrophages and directly regulated by PPAR gamma activators. Biochem Biophys Res Commun 300 (2003) 472-476
211. Paz K., Voliovitch H., Hadari Y.R., Roberts Jr. C.T., LeRoith D., and Zick Y. Interaction between the insulin receptor and its downstream effectors. Use of individually expressed receptor domains for structure/function analysis. J Biol Chem 271 (1996) 6998-7003
212. Paz K., Hemi R., LeRoith D., Karasik A., Elhanany E., Kanety H., et al. A molecular basis for insulin resistance. Elevated serine/threonine phosphorylation of IRS-1 and IRS-2 inhibits their binding to the juxtamembrane region of the insulin receptor and impairs their ability to undergo insulin-induced tyrosine phosphorylation. J Biol Chem 272 (1997) 29911-29918
213. Pederson T.M., Kramer D.L., and Rondinone C.M. Serine/threonine phosphorylation of IRS-1 triggers its degradation: possible regulation by tyrosine phosphorylation. Diabetes 50 (2001) 24-31
214. Perez C., Fernandez-Galaz C., Fernandez-Agullo T., Arribas C., Andres A., Ros M., et al. Leptin impairs insulin signaling in rat adipocytes. Diabetes 53 (2004) 347-353
215. Pezzetti F., Martinelli M., Scapoli L., Carinci F., Palmieri A., Marchesini J., et al. Maternal MTHFR variant forms increase the risk in offspring of isolated nonsyndromic cleft lip with or without cleft palate. Human Mutat 24 (2004) 104-105
216. Pickavance L.C., Brand C.L., Wassermann K., and Wilding J.P. The dual PPARalpha/gamma agonist, ragaglitazar, improves insulin sensitivity and metabolic profile equally with pioglitazone in diabetic and dietary obese ZDF rats. Br J Pharmacol 144 (2005) 308-316
217. Pittas A.G., Joseph N.A., and Greenberg A.S. Adipocytokines and insulin resistance. J Clin Endocrinol Metab 89 (2004) 447-452
218. Powers, A. C. (2005). Chapter 323. Diabetes mellitus. In D. L. Kasper, A. S. Fauci, D. L. Longo, E. Braunwald, S. L. Hauser, & J. L. Jameson, Harrison's principles of internal medicine (16th ed.). The McGraw-Hill Companies, Inc.
219. Quinones M.J., Hernandez-Pampaloni M., Schelbert H., Bulnes-Enriquez I., Jimenez X., Hernandez G., et al. Summaries for patients. Insulin resistance is associated with abnormalities of coronary arteries in people without other cardiac risk factors. Ann Intern Med 140 (2004) 1-32
220. Quinones M.J., Hernandez-Pampaloni M., Schelbert H., Bulnes-Enriquez I., Jimenez X., Hernandez G., et al. Coronary vasomotor abnormalities in insulin-resistant individuals. Ann Intern Med 140 (2004) 700-708
221. Ragolia L., and Begum N. Protein phosphatase-1 and insulin action. Mol Cell Biochem 182 (1998) 49-58
222. Rajagopalan R., Rosenson R.S., Fernandes A.W., Khan M., and Murray F.T. Association between congestive heart failure and hospitalization in patients with type 2 diabetes mellitus receiving treatment with insulin or pioglitazone: a retrospective data analysis. Clin Ther 26 (2004) 1400-1410
223. Rajala M.W., Obici S., Scherer P.E., and Rossetti L. Adipose-derived resistin and gut-derived resistin-like molecule-beta selectively impair insulin action on glucose production. J Clin Invest 111 (2003) 225-230
224. Randle P.J. Regulatory interactions between lipids and carbohydrates: the glucose fatty acid cycle after 35 years. Diabetes Metab Rev 14 (1998) 263-283
225. Randle P.J., Garland P.B., Hales C.N., and Newsholme E.A. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1 (1963) 785-789
226. Rangwala S.M., and Lazar M.A. The dawn of the SPPARMs?. Science's STKE (2002) PE9
227. Rangwala S.M., and Lazar M.A. Peroxisome proliferator-activated receptor gamma in diabetes and metabolism. Trends Pharmacol Sci 25 (2004) 331-336
228. Rangwala S.M., Rhoades B., Shapiro J.S., Rich A.S., Kim J.K., Shulman G.I., et al. Genetic modulation of PPARgamma phosphorylation regulates insulin sensitivity. Dev Cell 5 (2003) 657-663
229. Raskin P., Rendell M., Riddle M.C., Dole J.F., Freed M.I., Rosenstock J., et al. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care 24 (2001) 1226-1232
230. Reaven G.M., Hollenbeck C., Jeng C.Y., Wu M.S., and Chen Y.D. Measurement of plasma glucose, free fatty acid, lactate, and insulin for 24 h in patients with NIDDM. Diabetes 37 (1988) 1020-1024
231. Reddy J.K., and Rao M.S. Peroxisome proliterators and cancer: mechanisms and implications. Trends Pharmacol Sci 7 (1986) 438-443
232. Reshef L., Olswang Y., Cassuto H., Blum B., Croniger C.M., Kalhan S.C., et al. Glyceroneogenesis and the triglyceride/fatty acid cycle. J Biol Chem 278 (2003) 30413-30416
233. Ribon V., and Saltiel A.R. Insulin stimulates tyrosine phosphorylation of the proto-oncogene product of c-Cbl in 3T3-L1 adipocytes. Biochem J 324 (1997) 839-845
234. Ribon V., Johnson J.H., Camp H.S., and Saltiel A.R. Thiazolidinediones and insulin resistance: peroxisome proliferatoractivated receptor gamma activation stimulates expression of the CAP gene. Proc Natl Acad Sci U S A 95 (1998) 14751-14756
235. Roden M. Non-invasive studies of glycogen metabolism in human skeletal muscle using nuclear magnetic resonance spectroscopy. Curr Opin Clin Nutr Metab Care 4 (2001) 261-266
236. Roden M. How free fatty acids inhibit glucose utilization in human skeletal muscle. News Physiol Sci 19 (2004) 92-96
237. Roden M., Price T.B., Perseghin G., Petersen K.F., Rothman D.L., Cline G.W., et al. Mechanism of free fatty acid-induced insulin resistance in humans. J Clin Invest 97 (1996) 2859-2865
238. Rodrigues B., Cam M.C., and McNeill J.H. Metabolic disturbances in diabetic cardiomyopathy. Mol Cell Biochem 180 (1998) 53-57
239. Rondinone C.M., Wang L.M., Lonnroth P., Wesslau C., Pierce J.H., and Smith U. Insulin receptor substrate (IRS) 1 is reduced and IRS-2 is the main docking protein for phosphatidylinositol 3-kinase in adipocytes from subjects with non-insulin-dependent diabetes mellitus. Proc Natl Acad Sci U S A 94 (1997) 4171-4175
240. Rosen E.D., and Spiegelman B.M. PPARgamma: a nuclear regulator of metabolism, differentiation, and cell growth. J Biol Chem 276 (2001) 37731-37734
241. Rosen O.M., Herrera R., Olowe Y., Petruzzelli L.M., and Cobb M.H. Phosphorylation activates the insulin receptor tyrosine protein kinase. J Biol Chem 80 (1983) 3237-3240
242. Rosen E.D., Sarraf P., Troy A.E., Bradwin G., Moore K., Milstone D.S., et al. PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro. Mol Cell 4 (1999) 611-617
243. Rosenblatt-Velin N., Lerch R., Papageorgiou I., and Montessuit C. Insulin resistance in adult cardiomyocytes undergoing dedifferentiation: role of GLUT4 expression and translocation. FASEB J 18 (2004) 872-874
244. Rothman D.L., Shulman R.G., and Shulman G.I. 31P nuclear magnetic resonance measurements of muscle glucose-6-phosphate. Evidence for reduced insulin-dependent muscle glucose transport or phosphorylation activity in non-insulin-dependent diabetes mellitus. J Clin Invest 89 (1992) 1069-1075
245. Rothman D.L., Magnusson I., Cline G., Gerard D., Kahn C.R., Shulman R.G., et al. Decreased muscle glucose transport/phosphorylation is an early defect in the pathogenesis of non-insulin-dependent diabetes mellitus. Proc Natl Acad Sci U S A 92 (1995) 983-987
246. Rotter V., Nagaev I., and Smith U. Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-alpha, overexpressed in human fat cells from insulin-resistant subjects. J Biol Chem 278 (2003) 45777-45784
247. Ruan H., Pownall H.J., and Lodish H.F. Troglitazone antagonizes tumor necrosis factor-alpha-induced reprogramming of adipocyte gene expression by inhibiting the transcriptional regulatory functions of NF-kappaB. J Biol Chem 278 (2003) 28181-28192
248. Rubin C.S., Hirsch A., Fung C., and Rosen O.M. Development of hormone receptors and hormonal responsiveness in vitro. Insulin receptors and insulin sensitivity in the preadipocyte and adipocyte forms of 3T3-L1 cells. J Biol Chem 253 (1978) 7570-7578
249. Ryan M.J., Didion S.P., Mathur S., Faraci F.M., and Sigmund C.D. PPAR (gamma) agonist rosiglitazone improves vascular function and lowers blood pressure in hypertensive transgenic mice. Hypertension 43 (2004) 661-666
250. Ryden M., Arvidsson E., Blomqvist L., Perbeck L., Dicker A., and Arner P. Targets for TNF-alpha-induced lipolysis in human adipocytes. Biochem Biophys Res Commun 318 (2004) 168-175
251. Ryden M., Dicker A., van Harmelen V., Hauner H., Brunnberg M., Perbeck L., et al. Mapping of early signaling events in tumor necrosis factor-alpha-mediated lipolysis in human fat cells. J Biol Chem 277 (2002) 1085-1091
252. Saltiel A.R. Series introduction: the molecular and physiological basis of insulin resistance: emerging implications for metabolic and cardiovascular diseases. J Clin Invest 106 (2000) 163-164
253. Saltiel A.R., and Kahn C.R. Insulin signalling and the regulation of glucose and lipid metabolism. Nature 414 (2001) 799-806
254. Samuelsson L., Stromberg K., Vikman K., Bjursell G., and Enerback S. The CCAAT/enhancer binding protein and its role in adipocyte differentiation: evidence for direct involvement in terminal adipocyte development. EMBO J 10 (1991) 3787-3793
255. Satoh S., Nishimura H., Clark A.E., Kozka I.J., Vannucci S.J., Simpson I.A., et al. Use of bismannose photolabel to elucidate insulin-regulated GLUT4 subcellular trafficking kinetics in rat adipose cells. Evidence that exocytosis is a critical site of hormone action. J Biol Chem 268 (1993) 17820-17829
256. Satoh N., Ogawa Y., Usui T., Tagami T., Kono S., Uesugi H., et al. Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. Diabetes Care 26 (2003) 2493-2499
257. Scherer P.E., Williams S., Fogliano M., Baldini G., and Lodish H.F. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 270 (1995) 26746-26749
258. Schafer K., Fujisawa K., Konstantinides S., and Loskutoff D.J. Disruption of the plasminogen activator inhibitor 1 gene reduces the adiposity and improves the metabolic profile of genetically obese and diabetic ob/ob mice. FASEB J 15 (2001) 1840-1842
259. Senn J.J., Klover P.J., Nowak I.A., and Mooney R.A. Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes 51 (2002) 3391-3399
260. Sesti G., Federici M., Hribal M.L., Lauro D., Sbraccia P., and Lauro R. Defects of the insulin receptor substrate (IRS) system in human metabolic disorders. FASEB J 15 (2001) 2099-2111
261. Seufert J., Lubben G., Dietrich K., and Bates P.C. A comparison of the effects of thiazolidinediones and metformin on metabolic control in patients with type 2 diabetes mellitus. Clin Ther 26 (2004) 805-818
262. Shafrir E. Development and consequences of insulin resistance: lessons from animals with hyperinsulinaemia. Diabetes Metab 22 (1996) 122-131
263. Shah M., Kolandaivelu A., and Fearon W.F. Pioglitazone-induced heart failure despite normal left ventricular function. Am J Med 117 (2004) 973-974
264. Shao D., Rangwala S.M., Bailey S.T., Krakow S.L., Reginato M.J., and Lazar M.A. Interdomain communication regulating ligand binding by PPAR gamma. Nature 396 (1998) 377-380
265. Sheehan J.P. Fasting hyperglycemia: etiology, diagnosis, and treatment. Diabetes Technol Ther 6 (2004) 525-533
266. Shepherd P.R., Withers D.J., and Siddle K. Phosphoinositide 3-kinase: the key switch mechanism in insulin signalling. Biochem J 333 (1998) 471-490
267. Shimizu H., Tsuchiya T., Sato N., Shimomura Y., Kobayashi I., and Mori M. Troglitazone reduces plasma leptin concentration but increases hunger in NIDDM patients. Diabetes Care 21 (1998) 1470-1474
268. Shimomura I., Funahashi T., Takahashi M., Maeda K., Kotani K., Nakamura T., et al. Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity. Nat Med 2 (1996) 800-803
269. Shimomura I., Hammer R.E., Ikemoto S., Brown M.S., and Goldstein J.L. Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. Nature 401 (1999) 73-76
270. Shiomi T., Tsutsui H., Hayashidani S., Suematsu N., Ikeuchi M., Wen J., et al. Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 106 (2002) 3126-3132
271. Shojima N., Sakoda H., Ogihara T., Fujishiro M., Katagiri H., Anai M., et al. Humoral regulation of resistin expression in 3T3-L1 and mouse adipose cells. Diabetes 51 (2002) 1737-1744
272. Shulman G.I. Cellular mechanisms of insulin resistance. J Clin Invest 106 (2000) 171-176
273. Sidell R.J., Cole M.A., Draper N.J., Desrois M., Buckingham R.E., and Clarke K. Thiazolidinedione treatment normalizes insulin resistance and ischemic injury in the Zucker fatty rat heart. Diabetes 51 (2002) 1110-1117
274. Sigrist S., Bedoucha M., and Boelsterli U.A. Down-regulation by troglitazone of hepatic tumor necrosis factor-alpha and interleukin-6 mRNA expression in a murine model of non-insulin-dependent diabetes. Biochem Pharmacol 60 (2000) 67-75
275. Skrumsager B.K., Nielsen K.K., Muller M., Pabst G., Drake P.G., and Edsberg B. Ragaglitazar: the pharmacokinetics, pharmacodynamics, and tolerability of a novel dual PPAR alpha and gamma agonist in healthy subjects and patients with type 2 diabetes. J Clin Pharmacol 43 (2003) 1244-1256
276. Song J., Knepper M.A., Hu X., Verbalis J.G., and Ecelbarger C.A. Rosiglitazone activates renal sodium- and water-reabsorptive pathways and lowers blood pressure in normal rats. J Pharmacol Exp Ther 308 (2004) 426-433
277. Sowers J.R., and Stump C.S. Insights into the biology of diabetic vascular disease: what's new?. Am J Hypertens 17 (2004) S2-S6
278. Srivastava P.M., Calafiore P., MacIsaac R.J., Hare D.L., Jerums G., and Burrell L.M. Thiazolidinediones and congestive heart failure-exacerbation or new onset of left ventricular dysfunction?. Diabet Med 21 (2004) 945-950
279. Stadtmauer L., and Rosen O.M. Increasing the cAMP content of IM-9 cells alters the phosphorylation state and protein kinase activity of the insulin receptor. J Biol Chem 261 (1986) 3402-3407
280. Stephens J.M., and Pekala P.H. Transcriptional repression of the GLUT4 and C/EBP genes in 3T3-L1 adipocytes by tumor necrosis factor-alpha. J Biol Chem 266 (1991) 21839-21845
281. Stephens J.M., and Pekala P.H. Transcriptional repression of the C/EBP-alpha and GLUT4 genes in 3T3-L1 adipocytes by tumor necrosis factor-alpha. Regulations are coordinate and independent of protein synthesis. J Biol Chem 267 (1992) 13580-13584
282. Stephens J.M., Lee J., and Pilch P.F. Tumor necrosis factor-alpha-induced insulin resistance in 3T3-L1 adipocytes is accompanied by a loss of insulin receptor substrate-1 and GLUT4 expression without a loss of insulin receptor-mediated signal transduction. J Biol Chem 272 (1997) 971-976
283. Steppan C.M., Bailey S.T., Bhat S., Brown E.J., Banerjee R.R., Wright C.M., et al. The hormone resistin links obesity to diabetes. Nature 409 (2001) 307-312
284. St John Sutton M., Rendell M., Dandona P., Dole J.F., Murphy K., Patwardhan R., et al. A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes. Diabetes Care 25 (2002) 2058-2064
285. Stolar M.W., and Chilton R.J. Type 2 diabetes, cardiovascular risk, and the link to insulin resistance. Clin Ther 25 Suppl B (2003) B4-B31
286. Sun X.J., Rothenberg P., Kahn C.R., Backer J.M., Araki E., Wilden P.A., et al. Structure of the insulin receptor substrate IRS-1 defines a unique signal transduction protein. Nature 352 (1991) 73-77
287. Tack C.J., Smits P., Demacker P.N., and Stalenhoef A.F. Troglitazone decreases the proportion of small, dense LDL and increases the resistance of LDL to oxidation in obese subjects. Diabetes Care 21 (1998) 796-799
288. Takahashi T., Morita K., Akagi R., and Sassa S. Heme oxygenase-1: a novel therapeutic target in oxidative tissue injuries. Curr Med Chem 11 (2004) 1545-1561
289. Takata Y., Kitami Y., Yang Z.H., Nakamura M., Okura T., and Hiwada K. Vascular inflammation is negatively autoregulated by interaction between CCAAT/enhancer-binding protein-delta and peroxisome proliferator-activated receptor-gamma. Circ Res 91 (2002) 427-433
290. Tang W.H., Francis G.S., Hoogwerf B.J., and Young J.B. Fluid retention after initiation of thiazolidinedione therapy in diabetic patients with established chronic heart failure. J Am Coll Cardiol 41 (2003) 1394-1398
291. Tchkonia T., Giorgadze N., Pirtskhalava T., Tchoukalova Y., Karagiannides I., Forse R.A., et al. Fat depot origin affects adipogenesis in primary cultured and cloned human preadipocytes. Am J Physiol Regul Integr Comp Physiol 282 (2002) R1286-R1296
292. Teboul L., Febbraio M., Gaillard D., Amri E.Z., Silverstein R., and Grimaldi P.A. Structural and functional characterization of the mouse fatty acid translocase promoter: activation during adipose differentiation. Biochem J 360 (2001) 305-312
293. Thiemermann C. Ligands of the peroxisome proliferator-activated receptor-gamma and heart failure. Br J Pharmacol 142 (2004) 1049-1051
294. Thirone A.C., Carvalheira J.B., Hirata A.E., Velloso L.A., and Saad M.J. Regulation of Cbl-associated protein/Cbl pathway in muscle and adipose tissues of two animal models of insulin resistance. Endocrinology 145 (2004) 281-293
295. Tomlinson J.W., Moore J., Cooper M.S., Bujalska I., Shahmanesh M., Burt C., et al. Regulation of expression of 11ß-hydroxysteroid dehydrogenase type 1 in adipose tissue: tissue-specific induction by cytokines. Endocrinology 142 (2001) 1982-1989
296. Tomlinson J.W., Walker E.A., Bujalska I.J., Draper N., Lavery G.G., Cooper M.S., et al. 11 beta-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response. Endocr Rev 25 (2004) 831-866
297. Tontonoz P., Hu E., and Spiegelman B.M. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell 79 (1994) 1147-1156
298. Tontonoz P., Hu E., Devine J., Beale E.G., and Spiegelman B.M. PPAR gamma 2 regulates adipose expression of the phosphoenolpyruvate carboxykinase gene. Mol Cell Biol 15 (1995) 351-357
299. Tontonoz P., Nagy L., Alvarez J.G., Thomazy V.A., and Evans R.M. PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 93 (1998) 241-252
300. Tsuji T., Mizushige K., Noma T., Murakami K., Ohmori K., Miyatake A., et al. Pioglitazone improves left ventricular diastolic function and decreases collagen accumulation in prediabetic stage of a type II diabetic rat. J Cardiovasc Pharmacol 38 (2001) 868-874
301. Tsuruzoe K., Emkey R., Kriauciunas K.M., Ueki K., and Kahn C.R. Insulin receptor substrate 3 (IRS-3) and IRS-4 impair IRS-1- and IRS-2-mediated signaling. Mol Cell Biol 21 (2001) 26-38
302. Uppenberg J., Svensson C., Jaki M., Bertilsson G., Jendeberg L., and Berkenstam A. Crystal structure of the ligand binding domain of the human nuclear receptor PPARgamma. J Biol Chem 273 (1998) 31108-31112
303. Vaag A., Skott P., Damsbo P., Gall M.A., Richter E.A., and Beck-Nielsen H. Effect of the antilipolytic nicotinic acid analogue acipimox on whole-body and skeletal muscle glucose metabolism in patients with non-insulin-dependent diabetes mellitus. J Clin Invest 88 (1991) 1282-1290
304. Valverde A.M., Teruel T., Navarro P., Benito M., and Lorenzo M. Tumor necrosis factor-alpha causes insulin receptor substrate-2-mediated insulin resistance and inhibits insulin-induced adipogenesis in fetal brown adipocytes. Endocrinology 139 (1998) 1229-1238
305. Van Putten J.P., Wieringa T., and Krans H.M. Corticosteroids as long-term regulators of the insulin effectiveness in mouse 3T3 adipocytes. Diabetologia 28 (1985) 445-451
306. Velussi M. MCC-555 (Mitsubishi-Tokyo Pharmaceuticals). IDrugs 4 (2001) 586-589
307. Verreth W., De Keyzer D., Pelat M., Verhamme P., Ganame J., Bielicki J.K., et al. Weight loss-associated induction of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma correlate with reduced atherosclerosis and improved cardiovascular function in obese insulin-resistant mice. Circulation 110 (2004) 3259-3269
308. Wajchenberg B.L. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev 21 (2000) 697-738
309. Wang M., and Tafuri S. Modulation of PPARgamma activity with pharmaceutical agents: treatment of insulin resistance and atherosclerosis. J Cell Biochem 89 (2003) 38-47
310. Wang J., Obici S., Morgan K., Barzilai N., Feng Z., and Rossetti L. Overfeeding rapidly induces leptin and insulin resistance. Diabetes 50 (2001) 2786-2791
311. Wang N., Verna L., Chen N.G., Chen J., Li H., Forman B.M., et al. Constitutive activation of peroxisome proliferator-activated receptor-gamma suppresses pro-inflammatory adhesion molecules in human vascular endothelial cells. J Biol Chem 277 (2002) 34176-34181
312. Wang C.H., Weisel R.D., Liu P.P., Fedak P.W., and Verma S. Glitazones and heart failure: critical appraisal for the clinician. Circulation 107 (2003) 1350-1354
313. Wang F., Vergara C., Carabino J., Desilets A., and Vasquez R. Continuation of thiazolidinedione therapy in patients without left ventricular dysfunction who developed edema and congestive-heart-failure symptoms. Am J Health-Syst Pharm 61 15 (2004) 1604-1608
314. Wannamethee S.G., and Shaper A.G. Weight change and duration of overweight and obesity in the incidence of type 2 diabetes. Diabetes Care 22 (1999) 1266-1272
315. Watson R.T., and Pessin J.E. Intracellular organization of insulin signaling and GLUT4 translocation. Recent Prog Horm Res 56 (2001) 175-193
316. Wayman N.S., Hattori Y., McDonald M.C., Mota-Filipe H., Cuzzocrea S., Pisano B., et al. Ligands of the peroxisome proliferator-activated receptors (PPAR-gamma and PPAR-alpha) reduce myocardial infarct size. FASEB J 16 (2002) 1027-1040
317. Wellen K.E., Uysal K.T., Wiesbrock S., Yang Q., Chen H., and Hotamisligil G.S. Interaction of tumor necrosis factor-alpha- and thiazolidinedione-regulated pathways in obesity. Endocrinology 145 (2004) 2214-2220
318. White M.F., and Kahn C.R. The insulin signaling system. J Biol Chem 269 (1994) 1-4
319. White B.D., and Martin R.J. Evidence for a central mechanism of obesity in the Zucker rat: role of neuropeptide Y and leptin. Proc Soc Exp Biol Med 214 (1997) 222-232
320. White M.F., Shoelson S.E., Keutmann H., and Kahn C.R. A cascade of tyrosine autophosphorylation in the beta-subunit activates the phosphotransferase of the insulin receptor. J Biol Chem 263 (1988) 2969-2980
321. William, F.G. (2005). Chapter 19. Endocrine Functions of the Pancreas and Regulation of Carbohydrate Metabolism. Review of Medical Physiology (22nd ed.). The McGraw-Hill Companies, Inc.
322. Willson T.M., Cobb J.E., Cowan D.J., Wiethe R.W., Correa I.D., Prakash S.R., et al. The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones. J Med Chem 39 (1996) 665-668
323. Willson T.M., Brown P.J., Sternbach D.D., and Henke B.R. The PPARs: from orphan receptors to drug discovery. J Med Chem 43 (2000) 527-550
324. Winkler K., Konrad T., Fullert S., Friedrich I., Destani R., Baumstark M.W., et al. Pioglitazone reduces atherogenic dense LDL particles in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study. Diabetes Care 26 (2003) 2588-2594
325. Wolf G. The function of the nuclear receptor peroxisome proliferator-activated receptor delta in energy homeostasis. Nutr Rev 61 (2003) 387-390
326. Wright H.M., Clish C.B., Mikami T., Hauser S., Yanagi K., Hiramatsu R., et al. A synthetic antagonist for the peroxisome proliferator-activated receptor gamma inhibits adipocyte differentiation. J Biol Chem 275 (2000) 1873-1877
327. Wu Z., Xie Y., Bucher N.L., and Farmer S.R. Conditional ectopic expression of C/EBP beta in NIH-3T3 cells induces PPAR gamma and stimulates adipogenesis. Genes Dev 9 (1995) 2350-2363
328. Wu Z., Bucher N.L., and Farmer S.R. Induction of peroxisome proliferator-activated receptor gamma during the conversion of 3T3 fibroblasts into adipocytes is mediated by C/EBPbeta, C/EBPdelta, and glucocorticoids. Mol Cell Biol 16 (1996) 4128-4136
329. Wu Z., Xie Y., Morrison R.F., Bucher N.L., and Farmer S.R. PPAR-gamma induces the insulin-dependent glucose transporter GLUT4 in the absence of C/EBPalpha during the conversion of 3T3 fibroblasts into adipocytes. J Clin Invest 101 (1998) 22-32
330. Wu L., Wang R., De Champlain J., and Wilson T.W. Beneficial and deleterious effects of rosiglitazone on hypertension development in spontaneously hypertensive rats. Am J Hypertens 17 (2004) 749-756
331. Xu H.E., Stanley T.B., Montana V.G., Lambert M.H., Shearer B.G., Cobb J.E., et al. Structural basis for antagonist-mediated recruitment of nuclear co-repressors by PPARalpha. Nature 415 (2002) 813-817
332. Xu Y., Lu L., Greyson C., Lee J., Gen M., Kinugawa K., et al. Deleterious effects of acute treatment with a peroxisome proliferator-activated receptor-gamma activator in myocardial ischemia and reperfusion in pigs. Diabetes 52 (2003) 1187-1194
333. Xu Y., Gen M., Lu L., Fox J., Weiss S.O., Brown R.D., et al. PPAR-{gamma} activation fails to provide myocardial protection in ischemia and reperfusion in pigs. Am J Physiol Heart Circ Physiol 288 (2005) H1314-H1323
334. Yamamoto-Honda R., Kadowaki T., Momomura K., Tobe K., Tamori Y., Shibasaki Y., et al. Normal insulin receptor substrate-1 phosphorylation in autophosphorylation-defective truncated insulin receptor. Evidence that phosphorylation of substrates might be sufficient for certain biological effects evoked by insulin. J Biol Chem 268 (1993) 16859-16865
335. Yamamoto K., Ohki R., Lee R.T., Ikeda U., and Shimada K. Peroxisome proliferator-activated receptor gamma activators inhibit cardiac hypertrophy in cardiac myocytes. Circulation 104 (2001) 1670-1675
336. Yamauchi T., Kamon J., Waki H., Murakami K., Motojima K., Komeda K., et al. The mechanisms by which both heterozygous peroxisome proliferator-activated receptor gamma (PPARgamma) deficiency and PPARgamma agonist improve insulin resistance. J Biol Chem 276 (2001) 41245-41254
337. Yamauchi T., Kamon J., Waki H., Terauchi Y., Kubota N., Hara K., et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7 (2001) 941-946
338. Yang J., and Holman G.D. Comparison of GLUT4 and GLUT1 subcellular trafficking in basal and insulin-stimulated 3T3-L1 cells. J Biol Chem 268 (1993) 4600-4603
339. Yang W.S., Jeng C.Y., Wu T.J., Tanaka S., Funahashi T., Matsuzawa Y., et al. Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabetes Care 25 (2002) 376-380
340. Ye J.M., Iglesias M.A., Watson D.G., Ellis B., Wood L., Jensen P.B., et al. PPARalpha /gamma ragaglitazar eliminates fatty liver and enhances insulin action in fat-fed rats in the absence of hepatomegaly. Am J Physiol Endocrinol Metab 284 (2003) E531-E540
341. Yeh W.C., Cao Z., Classon M., and McKnight S.L. Cascade regulation of terminal adipocyte differentiation by three members of the C/EBP family of leucine zipper proteins. Genes Dev 9 (1995) 168-181
342. Yosefy C., Magen E., Kiselevich A., Priluk R., London D., Volchek L., et al. Rosiglitazone improves, while Glibenclamide worsens blood pressure control in treated hypertensive diabetic and dyslipidemic subjects via modulation of insulin resistance and sympathetic activity. J Cardiovasc Pharmacol 44 (2004) 215-222
343. Yoshioka T., Fujita T., Kanai T., Aizawa Y., Kurumada T., Hasegawa K., et al. Studies on hindered phenols and analogues: 1. Hypolipidemic and hypoglycemic agents with ability to inhibit lipid peroxidation. J Med Chem 32 (1989) 421-428
344. Yu C., Chen Y., Cline G.W., Zhang D., Zong H., Wang Y., et al. Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle. J Biol Chem 277 (2002) 50230-50236
345. Yu J.G., Javorschi S., Hevener A.L., Kruszynska Y.T., Norman R.A., Sinha M., et al. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes 51 (2002) 2968-2974
346. Yue T.L., Chen J., Bao W., Narayanan P.K., Bril A., Jiang W., et al. In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. Circulation 104 (2001) 2588-2594
347. Yuri K., Megan C.H., Ann B., Pamela M.H., Dieter S., Pauline J., et al. 11-beta-Hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress. Proc Natl Acad Sci U S A 94 (1997) 14924-14929
348. Zhang F., Sowers J.R., Ram J.L., Standley P.R., and Peuler J.D. Effects of pioglitazone on calcium channels in vascular smooth muscle. Hypertension 24 (1994) 170-175
349. Zhang Y., Proenca R., Maffei M., Barone M., Leopold L., and Friedman J.M. Positional cloning of the mouse obese gene and its human homologue. Nature 372 (1994) 425-432
350. Zhou J., Wilson K.M., and Medh J.D. Genetic analysis of four novel peroxisome proliferator activated receptor-gamma splice variants in monkey macrophages. Biochem Biophys Res Commun 293 (2002) 274-283
351. Zhu P., Lu L., Xu Y., and Schwartz G.G. Troglitazone improves recovery of left ventricular function after regional ischemia in pigs. Circulation 101 (2000) 1165-1171
352. Zick Y., Grunberger G., Podskalny J.M., Moncada V., Taylor S.I., Gorden P., et al. Insulin stimulates phosphorylation of serine residues in soluble insulin receptors. Biochem Biophys Res Commun 116 (1983) 1129-1135
353. Zimmet P., Alberti K.G., and Shaw J. Global and societal implications of the diabetes epidemic. Nature 414 (2001) 782-787
354. Zingarelli B., Sheehan M., Hake P.W., O'Connor M., Denenberg A., and Cook J.A. Peroxisome proliferator activator receptor-gamma ligands, 15-deoxy-Delta (12, 14)-prostaglandin J2 and ciglitazone, reduce systemic inflammation in polymicrobial sepsis by modulation of signal transduction pathways. J Immunol 171 (2003) 6827-6837
355. Zirlik A., Leugers A., Lohrmann J., Ernst S., Sobel B.E., Bode C., et al. Direct attenuation of plasminogen activator inhibitor type-1 expression in human adipose tissue by thiazolidinediones. Thromb Haemost 91 (2004) 674-682
356. Zuckerman S.H., Kauffman R.F., and Evans G.F. Peroxisome proliferator-activated receptor alpha, gamma coagonist LY465608 inhibits macrophage activation and atherosclerosis in apolipoprotein E knockout mice. Lipids 37 (2002) 487-494